ClinicalTrials.gg
RecruitingNCT07464392Updated Apr 14, 2026

FMT for the Prevention of Infectious Complications in Patients With Moderately Severe and Severe Acute Pancreatitis

An interventional study of Fecal Microbiota Transplantation and Placebo in Acute Pancreatitis, sponsored by Changhai Hospital. Recruiting at 12 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-14.

Sponsored by Changhai Hospital · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Pancreatitis by Changhai Hospital — 7 open to participants now, 7 under way, none of them phase 3. Pancreatitis · Changhai Hospital.

Started
2026
with 1 other
No phase
6 of 16
4 open now
Registered
16th of 16
by date

Among the 16 studies in Pancreatitis by Changhai Hospital, this one is one of 2 that started in 2026, is one of 6 with no phase, and was the 16th registered.

Pancreatitis

558 studies on the registry are indexed under Pancreatitis; 165 are open to participants now.

Browse Pancreatitis studies →

Open to participants now

7 of the 16 studies in Pancreatitis by Changhai Hospital are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 112 Pancreatitis studies recruiting now, 62 (55%) set no upper age limit and 27 (24%) stop at 75 or younger; 14 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Pancreatitis by Changhai Hospital, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn whether fecal microbiota transplantation (FMT) works to prevent infections complications in patients in the late phase of moderately severe or severe acute pancreatitis.

Read the detailed description

This multicenter, randomized, double-blind, placebo-controlled trial evaluates whether fecal microbiota transplantation (FMT) works to prevent infectious complications in patients in the late phase of moderately severe and severe acute pancreatitis.

Approximately 150 eligible participants will be enrolled across 12 centers in China and randomly assigned to receive either FMT plus standard treatment or placebo plus standard treatment. The intervention is administered via nasojejunal tube once daily for five consecutive days.

The study will assess infection-related outcomes, organ function, nutritional status, gastrointestinal function, gut microbiota changes, need for additional interventions or surgery, mortality, antibiotic use, and healthcare utilization. Exploratory analyses will investigate inflammatory and immune responses, and explore a predictive model based on baseline gut microbiota characteristics and clinical indicators.

All analyses will follow the intention-to-treat principle, aiming to inform better treatment choices and ultimately improve patient outcomes and quality of life.

03

Conditions studied

  • Acute Pancreatitis

Keywords

  • Acute Pancreatitis
  • Moderately Severe Acute Pancreatitis
  • Severe Acute Pancreatitis
  • Fecal Microbiota Transplantation
  • Digestive System Diseases
  • Pancreatic Diseases
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 18 and 75 years
  • Diagnosed with moderately severe acute pancreatitis (MSAP) or severe acute pancreatitis (SAP) according to the Revised Atlanta Classification 2012, with CT severity index (CTSI) score > 4
  • Disease duration of 15 to 21 days
  • Already have a nasojejunal tube in place
  • No absolute to fecal microbiota transplantation
  • Voluntarily sign the written form

Exclusion criteria

Exclusion Criteria:

  • Concurrent severe systemic infection
  • Concurrent extra-intestinal organ infection requiring intervention with broad-spectrum antibiotics
  • Intestinal obstruction, active gastrointestinal bleeding, intestinal perforation, fulminant colitis, or toxic megacolon
  • Unable to tolerate enteral nutrition meeting 50% of caloric requirements due to severe diarrhea, significant fibrotic intestinal stricture, severe gastrointestinal bleeding, or high-output intestinal fistula
  • Pre-existing chronic organ dysfunction (heart, lung, liver, kidney, or hematologic system) prior to admission
  • Multiple organ dysfunction syndrome (MODS) with a confirmed duration exceeding 2 weeks
  • Active
  • disease or status (including solid organ or bone marrow transplantation, AIDS, long-term use of immunosuppressants or hormones)
  • Congenital or acquired immunodeficiency
  • Pregnancy or breastfeeding
  • Severe mental disorder
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    Fecal Microbiota Transplantation

    Fecal microbiota transplantation (FMT) liquid, 100 mL , administered via nasojejunal tube, once daily for 5 consecutive days, plus standard treatment.

    Biological: Fecal Microbiota Transplantation

  • Placebo comparator
    Placebo

    Sterile saline (0.9% sodium chloride) solution, 100 mL, administered via nasojejunal tube, once daily for 5 consecutive days, plus standard treatment. Placebo is identical in appearance to FMT to maintain blinding.

    Other: Placebo

Interventions

  • BiologicalFecal Microbiota Transplantation

    Fecal microbiota transplantation (FMT) liquid is a biological intervention consisting of processed and standardized human fecal microbiota from healthy donors, suspended in sterile saline with cryoprotectant.

  • OtherPlacebo

    Sterile saline (0.9% sodium chloride) solution, packaged identically to FMT liquid with opaque materials to maintain blinding, contains no active components and serves as a placebo control.

06

What researchers measure

Primary outcomes

  1. Incidence of Infectious Complications

    Proportion of participants developing any of the following infectious complications: Infected pancreatic necrosis Bacteremia Pneumonia Urosepsis Infected ascites All infections are weighted equally; multiple infections in the same patient are counted as a single endpoint.

    Time frame: Within 30 days after enrollment

Secondary outcomes

  1. Incidence of Infectious Complications

    Proportion of participants developing any infectious complications (as defined in the primary outcome)

    Time frame: Within 90 days after enrollment

  2. Organ Failure

    Incidence of organ failure assessed by Sequential Organ Failure Assessment (SOFA) score and modified Marshall score.

    Time frame: From enrollment to hospital discharge (up to 90 days)

  3. Enteral Nutrition Caloric Intake

    Daily enteral nutrition caloric intake assessed to evaluate adequacy of nutritional support. Reported in kcal/kg/day.

    Time frame: From enrollment to hospital discharge (up to 90 days)

  4. NUTRIC Score

    Nutrition Risk in Critically Ill (NUTRIC) score used to assess nutritional risk in ICU patients. Scores range from 0 to 10; higher scores indicate greater nutritional risk.

    Time frame: From enrollment to hospital discharge (up to 90 days)

  5. Subjective Global Assessment (SGA)

    Nutritional status assessed by Subjective Global Assessment. Patients are classified as: A (well-nourished), B (moderately malnourished), or C (severely malnourished).

    Time frame: Baseline, Day 30, Day 60, Day 90

  6. Serum Nutritional Protein Markers

    Serum levels of hemoglobin, albumin, and total protein measured to assess nutritional and metabolic status. Reported in g/L.

    Time frame: From enrollment to hospital discharge (up to 90 days)

  7. Serum Prealbumin

    Serum levels of prealbumin measured to assess nutritional and metabolic status. Reported in mg/L.

    Time frame: From enrollment to hospital discharge (up to 90 days)

  8. Serum Electrolyte Levels

    Serum levels of phosphorus and magnesium measured to assess electrolyte balance. Reported in mmol/L.

    Time frame: From enrollment to hospital discharge (up to 90 days)

  9. Body Mass Index (BMI)

    BMI calculated from measured height (meters) and weight (kilograms) to assess nutritional status. Reported in kg/m².

    Time frame: From enrollment to 90-day follow-up

  10. Gastrointestinal Symptom Rating Scale (GSRS)

    Gastrointestinal symptoms assessed using the simplified GSRS. Scores range from 0 to 42; higher scores indicate more severe symptoms.

    Time frame: From enrollment to 90-day follow-up

  11. Incidence of Gastrointestinal Adverse Events

    Daily monitoring from randomization to discharge of the following events: vomiting (≥1 episode/day), abdominal distension (assessed by daily abdominal circumference measurement), diarrhea (Bristol type 6-7 and ≥3 times/day), intestinal perforation, and abdominal bleeding. Reported in percentage of participants (%).

    Time frame: From enrollment to hospital discharge (up to 90 days)

  12. Serum Total Bile Acids Level

    Serum total bile acids measured to assess enterohepatic circulation and gut microbiota-mediated bile acid metabolism. Reported in μmol/L.

    Time frame: From enrollment to hospital discharge (up to 90 days)

  13. Serum Diamine Oxidase (DAO) Level

    Serum diamine oxidase level measured as a biomarker of intestinal mucosal barrier integrity and enterocyte damage. Reported in U/L.

    Time frame: From enrollment to hospital discharge (up to 90 days)

  14. Serum Endotoxin Level

    Serum endotoxin level measured to assess intestinal permeability and the degree of bacterial translocation across the gut barrier. Reported in EU/mL.

    Time frame: From enrollment to hospital discharge (up to 90 days)

  15. Serum D-Lactate Level

    Serum D-lactate level measured as a biomarker of intestinal mucosal permeability and bacterial overgrowth in the gastrointestinal tract. Reported in μmol/L.

    Time frame: From enrollment to hospital discharge (up to 90 days)

  16. Gut Microbiota Changes

    Changes in fecal microbiota composition and diversity assessed by metagenomic sequencing.

    Time frame: Baseline, Day 7, Day 30, Day 90

  17. Need for Additional Interventions or Surgery

    Proportion of participants requiring additional invasive interventions after FMT treatment.

    Time frame: From treatment initiation to 90-day follow-up

  18. Mortality

    All-cause mortality.

    Time frame: From enrollment to 90-day follow-up

  19. Antibiotic Utilization

    Proportion of participants receiving antibiotics and duration of antibiotic use.

    Time frame: From hospital admission to 90-day follow-up

  20. Hospital Length of Stay

    Duration of hospitalization (days).

    Time frame: From enrollment to hospital discharge (up to 90 days)

Other outcomes

  1. Hospital Total Costs

    Total hospitalization costs incurred during the index admission, including costs related to medication, procedures, nursing care, and ICU stay. Reported in CNY (Chinese Yuan).

    Time frame: From enrollment to hospital discharge (up to 90 days)

  2. Serum Cytokine Levels

    Serum levels of IL-6, IL-8, IL-10, and TNF-α measured to assess systemic inflammatory response. Reported in pg/mL.

    Time frame: From enrollment to hospital discharge (up to 90 days)

  3. Serum C-Reactive Protein (CRP) Level

    Serum CRP level measured as a marker of systemic inflammation. Reported in mg/L.

    Time frame: From enrollment to hospital discharge (up to 90 days)

  4. Serum Procalcitonin (PCT) Level

    Serum PCT level measured as a marker of infection and inflammatory response. Reported in ng/mL.

    Time frame: From enrollment to hospital discharge (up to 90 days)

  5. CD4+ and CD8+ T Cell Counts

    Peripheral blood CD4+ and CD8+ T lymphocyte counts measured to assess cellular immune function.

    Time frame: From enrollment to hospital discharge (up to 90 days)

  6. Immune Cell Indices

    Neutrophil CD64 index and CD4+/CD8+ ratio assessed to evaluate immune activation and balance.

    Time frame: From enrollment to hospital discharge (up to 90 days)

  7. Predictive Model Performance for Infectious Complications and FMT Response

    Predictive performance of a model based on baseline gut microbiota characteristics and clinical parameters to identify patients at high risk for infectious complications and to predict individual response to FMT treatment, evaluated by the area under the receiver operating characteristic curve (AUC-ROC).

    Time frame: From enrollment to 90-day follow-up

07

Study locations

1 of 12 sites recruiting
  • The Second Affiliated Hospital of Fujian University of Traditional Chinese Medicine
    Fuzhou, Fujian, China
    Not yet recruiting
    • Xiaoyan Fu · Contact13859021863
  • Quanzhou First Hospital, Fujian
    Quanzhou, Fujian, China
    Not yet recruiting
    • Yisen Huang · Contact13905983331
  • Guangdong Hospital of Traditional Chinese Medicine
    Guangzhou, Guangdong, China
    Not yet recruiting
    • Cailing Zhong · Contact13580565493
  • Guangzhou Medical University Affiliated Panyu Central Hospital
    Guangzhou, Guangdong, China
    Not yet recruiting
    • Yingying Zhao · Contact15673941051
  • The First Affiliated Hospital of Guangzhou Medical University
    Guangzhou, Guangdong, China
    Not yet recruiting
    • Peihong Wu · Contact13926599977
  • The Affiliated Qingyuan People's Hospital of Guangzhou Medical University
    Qingyuan, Guangdong, China
    Not yet recruiting
    • Donglian Liu · Contact13425262102
  • Affiliated Hospital of Guangdong Medical University
    Zhanjiang, Guangdong, China
    Not yet recruiting
    • Shicai Ye · Contact13360709925
  • Changhai Hospital
    Shanghai, Shanghai Municipality, China
    Recruiting
  • Renji Hospital, Shanghai Jiao Tong University School of Medicine
    Shanghai, Shanghai Municipality, China
    Not yet recruiting
    • Keji Zhang · Contact13817592023
    • Dan Lyu · Contact13764333620
  • Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
    Shanghai, Shanghai Municipality, China
    Not yet recruiting
    • Enqiang Mao · Contact13501747906
  • Shanghai General Hospital
    Shanghai, Shanghai Municipality, China
    Not yet recruiting
    • Yue Zeng · Contact18621625166
  • Shanghai Tenth People's Hospital ,Tenth People's Hospital Affiliated to Tongji University)
    Shanghai, Shanghai Municipality, China
    Not yet recruiting
    • Feng Liu · Contact13681973214
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Jul 2027, 15 months after the start.

Of 92 non-industry interventional studies with no phase under Pancreatitis, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 59. This study's planned 15 months is below that.

Counting every sponsor, half of 95 studies reached it within 32 months; a quarter within 23 and three quarters within 59.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 1, 2026
First posted
Mar 11, 2026
StartActual
Apr 2, 2026
Primary completionEst.
Jul 30, 2027
CompletionEst.
Sep 30, 2027
Last update
Apr 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07464392
Lead sponsor
Changhai Hospital
Responsible party
Xiangyu Kong (Associate Professor, Changhai Hospital) — Principal investigator
First posted
Mar 11, 2026
Start date
Apr 2, 2026
Primary completion
Jul 30, 2027 (estimated)
Completion
Sep 30, 2027 (estimated)
Last update
Apr 14, 2026

Study contacts

Xiang yu Kong, MD
Contact
xiangyukong185@hotmail.com
13564644397
Yiqi Du, MD
study chair · The First Affiliated Hospital of Naval Medical University (Shanghai Changhai Hospital)
Xiangyu Kong, MD
principal investigator · The First Affiliated Hospital of Naval Medical University (Shanghai Changhai Hospital)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion